UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Treatment of acute exacerbations of multiple sclerosis in adults

Authors
Michael J Olek, DO
Jonathan Howard, MD
Section Editor
Francisco González-Scarano, MD
Deputy Editor
John F Dashe, MD, PhD

INTRODUCTION

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system that is a leading cause of disability in young adults.

Despite dramatic advances in the clinical assessment of MS due to the widespread availability of brain and spine MRI, our understanding of the basic etiology of the disease remains limited. Full control of the disease and the repair of damaged myelin are key objectives for current and future investigators.

The treatment of acute exacerbations of MS is reviewed here. Other aspects of MS treatment are discussed separately. (See "Disease-modifying treatment of relapsing-remitting multiple sclerosis in adults" and "Treatment of progressive multiple sclerosis in adults" and "Symptom management of multiple sclerosis in adults".)

INDICATIONS

Attacks in MS are defined as episodes of focal neurologic disturbance lasting longer than 24 hours with a preceding period of clinical stability of at least 30 days and without an alternate explanation such as infection or fever. Indications for treatment of an acute attack (eg, relapse, exacerbation, flare) in patients with MS include functionally disabling symptoms with objective evidence of neurologic impairment such as loss of vision, diplopia weakness, and/or cerebellar symptoms. Mild sensory attacks often are not treated in the same manner, although symptomatic relief is sometimes necessary because of patient discomfort (eg, due to paresthesia).

Most patients with a suspected attack should be evaluated with an MRI of the brain or spinal cord, which will typically show a new lesion that enhances with the administration of gadolinium. This finding can help distinguish an attack from a "pseudo-relapse," the temporary worsening of existing MS symptoms in the setting of heat exposure or infection. However, an MRI is not obligatory if the clinical suspicion for an MS relapse is high or if the relapse is mild (eg, sensory only).

      

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Apr 2017. | This topic last updated: Aug 08, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000; 247:435.
  2. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61:1528.
  3. Galea I, Ward-Abel N, Heesen C. Relapse in multiple sclerosis. BMJ 2015; 350:h1765.
  4. Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology 1994; 44:1.
  5. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006; 332:525.
  6. Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; :CD001331.
  7. Burton JM, O'Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012; 12:CD006921.
  8. Le Page E, Veillard D, Laplaud DA, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 2015; 386:974.
  9. Barnes D, Hughes RA, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349:902.
  10. Martinelli V, Rocca MA, Annovazzi P, et al. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 2009; 73:1842.
  11. Morrow SA, Stoian CA, Dmitrovic J, et al. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 2004; 63:1079.
  12. Thompson AJ, Kennard C, Swash M, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39:969.
  13. Brod SA, Morales MM. Bio-equivalence of IM and SQ H.P. Acthar Gel. Biomed Pharmacother 2009; 63:251.
  14. Morrow SA, Barr J, Rosehart H, Ulch S. Depression and hypomania symptoms are associated with high dose corticosteroids treatment for MS relapses. J Affect Disord 2015; 187:142.
  15. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878.
  16. Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39:1143.
  17. Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 76:294.
  18. Ehler J, Koball S, Sauer M, et al. Response to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients. PLoS One 2015; 10:e0134583.
  19. Keegan M, König F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366:579.